<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04170140</url>
  </required_header>
  <id_info>
    <org_study_id>DNG00042</org_study_id>
    <secondary_id>U1111-1233-9599</secondary_id>
    <nct_id>NCT04170140</nct_id>
  </id_info>
  <brief_title>Study on Prescribers' Knowledge and Understanding of Safety Messages Following Dengvaxia® Product Information Update</brief_title>
  <acronym>DNG00042</acronym>
  <official_title>A Cross-sectional Survey to Evaluate Prescribers' Knowledge and Understanding of Safety Messages Following Dengvaxia® Product Information Update</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the effectiveness of additional risk
      minimization measures material by assessing the knowledge and understanding of healthcare
      professionals regarding the key safety messages provided in the material.

      The secondary objective of the study is to evaluate if healthcare professionals know
      Dengvaxia product information, namely, age indication and contraindications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a cross-sectional Survey. Study data are collected through a questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 7, 2020</start_date>
  <completion_date type="Actual">March 5, 2020</completion_date>
  <primary_completion_date type="Actual">March 5, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Healthcare professionals' knowledge and understanding of key safety messages provided in risk minimization measures materials</measure>
    <time_frame>Day 0</time_frame>
    <description>Knowledge and understanding of key safety messages are assessed through a questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Healthcare professionals' knowledge of Dengvaxia product information</measure>
    <time_frame>Day 0</time_frame>
    <description>Knowledge of Dengvaxia product information (age indication and contraindications) is assessed through a questionnaire</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">300</enrollment>
  <condition>Dengue Virus Infection</condition>
  <arm_group>
    <arm_group_label>Prescribers of Dengvaxia</arm_group_label>
    <description>Healthcare professionals who are current or past prescribers of Dengvaxia</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>Questionnaire</description>
    <arm_group_label>Prescribers of Dengvaxia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthcare professionals who are current or past prescribers of Dengvaxia
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

        - Healthcare professionals who are current or past prescribers of Dengvaxia

        Exclusion criteria:

          -  Healthcare professionals who have never prescribed Dengvaxia

          -  Healthcare professionals who may have a conflict of interest with the survey (i.e.
             Healthcare professionals employed by regulatory bodies, pharmaceutical industries)

          -  Healthcare professionales who have participated in testing the questionnaire for
             comprehensibility, consistency and the appropriateness of medical terms

        The above information is not intended to contain all considerations relevant to
        participation in the survey.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Real World Evidence Solutions IQVIA</name>
      <address>
        <city>La Defense</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

